DOCSLIB.ORG

55 Acrosome Membrane 34 Adenomyosis 115, 127 Adipocytes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
55 Acrosome Membrane 34 Adenomyosis 115, 127 Adipocytes Cambridge University Press 978-1-107-03447-1 - Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential: Third Edition Edited by Carlos Simón, Antonio Pellicer and Renee Reijo Pera Index More information Index Locators in italic refer to figures and tables a6 integrin (CD49f) 55 animal studies B-cells 81, 142 acrosome membrane 34 amniotic-fluid-derived stem cells Beckwith–Wiedemann syndrome 109, 110 37 adenomyosis 115, 127 bone-marrow-derived stem cells 125 adipocytes 105, 105–106 endometrial stem cells 121–122 beta-catenin 6,9 fetal surgery 134, 134–135, 136 beta1 integrin (CD29) 55 adult stem cells. See induced gamete generation 94 pluripotent stem cells See also mouse models bFGF growth factor 128 Advanced Cell Technology, Inc. 84 annexin-V-positive cells 38 bipolar disease 37 AFSC. See amniotic fluid-derived stem antigen-specific tolerance, in utero 133 blastocysts 84, 152 cells anti-Mullerian¨ hormone (AMH) 18 blastomeres age, maternal biopsy technique 84–85, linkage analysis 68–69 antimycin 167 86–88 non-disjunction 72 anti-oxidants 168, 169 cell autonomy 80, 81 AICAR (5-aminoimidazole gene expression 78 artificial insemination from viability diagnosis 79–80 carboxamide riboside) 173–174 anonymous donors (AID) 32, AID. See artificial insemination from 31–32, 32, 33,33 BLIMP1 gene expression 3, 16 anonymous donors Ascl1 (achaete-scute homolog 1) blood metastases 59 alkaline phosphatase (AP) 104 transcription factors 157 blood regeneration 110–111 allogeneic bone-marrow transfer 99 ascorbic acid 168 bone-marrow-derived stem cells alpha-MEM culture media 48 As model of stem-cell self-renewal 53, 124–125 54 Alzheimer’s disease 158 bone-marrow stroma 140, 143–144. assisted reproductive techniques See also mesenchymal stem ¨ AMH (anti-Mullerian hormone) 18 (ART) 15 cells amino acids 168, 172 ethics 95 bone morphogenetic protein 2 2, amniocentesis 103 sperm donation 32, 33 2–3 amniotic fluid-derived stem cells asthenozoospermia 35 bone morphogenetic protein 4 1, 2, 16, (AFSC) 102, 111–112 ATP metabolism 164–165, 172 52 characterization 104, 103–104, 105 authentic infertility, ethics 97 bone morphogenetic protein 7 clinical applications 108, 107–108, 105 108, 110, 111, 111 autism 37 bone morphogenetic protein 8B 1, 2, multipotency 105, 104–105, autoimmune disease 146 107 16, 52 See also gestational stem cells autologous reimplantation 103 bone regeneration 107, 108 amniotic sac 102 autosomal recessive osteoporosis, fetal brain tissue. See neuronal cells surgery 134–136 AMP-activated protein-kinase breast cancer resistance protein (AMPK) 173–174 azoospermia 34 (BCRP) 119 anemia, fetal surgery 134–136 BAF chromatin-remodeling complex bromodeoxyuridine (BrdU) label 115, Angelman syndrome 37 158 116, 117–118 animal cloning experiments Baf60c 158 Bub (Budding uninhibited by benzimidazole) proteins 23 152 bare lymphocyte syndrome 134 180 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-03447-1 - Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential: Third Edition Edited by Carlos Simón, Antonio Pellicer and Renee Reijo Pera Index More information Index cancer, epigenetics 37 clinical trials, hESCs 84 diakinesis/MI meiocytes 66 cancer patients colitis 146 differentiation, pluripotent cells blood metastases 59 collagen-induced arthritis 146 167–169 cryopreservation of testis 49–50 diplotene meiotic stage 23 fertility restoration 58, 57–58, 59 colony-forming units (CFUs) 117, spermatogonial stem cells 36 118–119, 126–127 direct lineage conversion. See transdifferentiation cancer stem cells (CSCs) 125–126 competitive advantage of fetal surgery 135 DNA integrity, spermatozoa 37–38 CAR cells (CXCL12-rich cells) 143, 144 COX gene expression 172 DNA methylation 37. See also cardiac cells 105, 159 crossover-associated proteins 67, 68,68 epigenetics cardiac transcription factors 158 cryopreservation of spermatogonial DNA polymorphisms 65–66 CD29 55 stem cells/testis 36, 49–50, 57, dogs, fetal surgery 135 CD30 172 58 Dolly the sheep 152 CD31 106 CTNNB1 (beta-catenin) 6,9 donor-recipient HLA matching 103 + CD45 bone-marrow cells 125 culture environments 170–173 donor-specific tolerance 133–134 CD49f (a6 integrin) 55 CXCL12 (chemokine (C-X-C motif) fetal surgery 136 CD133 55, 126 ligand 12) 4–5, 6, 143, 144 graft rejection 99 CD146 115, 122–124, 143 CXCR4 (chemokine (C-X-C motif) dopamine 143 receptor 4) 4–5, 6, 143, 144 CDH1. See E-cadherin dopaminergic neuron conversions 157 CYP26B1 (cytochrome P450 enzyme) double-strand breaks (DSBs) 64, 64–65 cell autonomy, blastomeres 80, 81 6,8 DPPA3. See STELLA cell cloning studies, endometrial stem cytochrome P450 18, 110 cells 117, 118–119 Drosophila cytokines 141 cell cycle controls 78 Hox gene 156 cytological analysis 66, 68, 67–68, stem-cell niches 54, 55–56 cell fusion, reprogramming 154 70–71 cell potency changes 153–154, 155 cytoplasmic endonucelase 24 E-cadherin 4–5,6 cell-based gene therapy 111 ectoderm cells 157, 164 DAX1 (nuclear receptor subfamily 0, ectopic tissue grafting 58–59 cell-of-origin memory 160–161 group B, member 1) 9–10 EGF growth factor 128 Centre d’Etude du Polymorphisme DAZ gene function 18, 22, 26 Humain (CEPH) 68 egg donation 15 DAZL (deleted in azoospermia-like) 5 centromere mapping 66,67 electron transport chain (ETC) 165 DDX4 (DEAD (Asp-Glu-Ala-Asp) box Chediak–Higashi syndrome 136 polypeptide 4) 5 embryo development and reprogramming 76 chemokines 141. See also CXCL12; DEAD-box gene family 26 CXCR4 imaging data 78–80, 81 dedifferentiation 154–156 and induced pluripotency 76–77 chiasmata, cytological analysis 66, definitions 154 novel analytic tools 81 67–68 default developmental path 8 oocyte-to-embryo transition 77–78 chimerism 124, 134 definitions embryo, moral status 95. See also ethics chondrocytes 106 azoospermia 34 embryo viability chromatin-modifying drugs 161 germ cells 1 and blastomere biopsy 86 chromatin remodeling 16, 17, 37 lineage conversion 154 prediction/diagnosis 79–80 niches 55 embryoid bodies (EBs) 20 chromatin-remodeling complex 157, pluripotency 164 158 transdifferentiation 154 embryonic stage-specific patterns (ESSPs) 80, 81 chromosome content, STCs 37 dendritic cells 141 chromosome number errors 63 embryonic stem cells (ESCs) 15, 36 desmosome-gap junction complexes 55 blastomere biopsy technique 84–85, chromosome 17, linkage analysis 69 developmental pluripotency-associated 86–88 chronic granulomatous disease 136 3. See STELLA cell cycle controls 78 diabetes mellitus 37 culture environment 170–173 c-kit membrane receptor 4, 6, 103, 124 developmental potency 152 181 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-03447-1 - Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential: Third Edition Edited by Carlos Simón, Antonio Pellicer and Renee Reijo Pera Index More information Index embryonic stem cells (ESCs) (cont.) factor VIII (FVIII) 106 genetic mapping techniques 66, 65–66, differentiation 21,22 female germline formation, PGCs 8, 68 energy metabolism 170 18. See also germline genetic status, SSCs 37 ethics 93, 94–97, 98, 99 development metabolic frameworks 166–174 genetically enhanced children 97 parthenote 85 fertility restoration, testicular SSCs 58, genome-wide analysis 120 57–58, 59 endoderm cells 157, 159, 164 genomics, massive analysis of sperm fetal bovine serum (FBS) 48 endometrial cancer 115, 125–126 39–40 fetal development, testicular SSCs GEO (Gene Expression Omnibus) endometrial regenerative capacity 52–53 115–116 database 120 fetal stem cells, remnant 124 endometrial stem/progenitor cells 115, germ-cell licensing 23 117–118, 127–128 fetal surgery 133–134, 136 germ-cell nuclear antigen 1 (GCNA1) characterization 116–117 animal studies 134–135, 136 5 clinical applications 125–127 clinical applications 134, 136 in vivo reconstitution 121–122 graft rejection 135–136 germ cells, definitions 1 markers 122–124 FGF9 (fibroblast growth factor 9) 6, germline development 15, 17, 26 menstrual blood 124 7–8 current challenges 22–26 mesenchymal stromal/stem cells in vitro generation 21, 20–21, 22 118–119, 120 fluorescence in situ hybridization mammals 16, 17, 16–17, 19 (FISH) 67 progenitor cell hypothesis 116, Geron, clinical trials 84 117–118 fluorescence-activated cell sorting side population cells 120, 121, (FACS) 46, 103 gestational stem cells 102–103, 111–112. See also amniotic 119–121, 123 FOLLISTATIN gene 8 sources 124–125 fluid-derived stem cells forkhead box L2 (FOXL2) 6,9 endometriosis 115, 126–127 GFAP+integrin ␤8+ 144 FRAGILIS gene 2,3,4,17 endothelial cells 105, 106 GFP (green fluorescent protein) 20, 54, FRIZZLED gene 8 125 energy metabolism, reprogramming 169–170 FST gene 6 GFP transgenes 47–48 epigenetic landscape model 154, GFP-negative ES cells 86 155, 156, 160–161 G1 and G2 cell cycle checkpoints 103, 104, 105 GFR␣1spermatogonialmarkers55 epigenetic memory 160–161 GABAergic transdifferentiation global decline in semen quality epigenetics 157 33–34 germline development 17, 17–19, gamete donation, ethics of 93. See 26 also ethics globozoospermia 35,35 spermatogenic cells 30 gamete generation glutamatergic transdifferentiation STCs 37 embryonic stem cells 94–97 157 erythroid cells 110–111 epigenetics 37 glutamine 165, 171 ESCs. See embryonic stem cells iPS cells 93–94 glycolytic metabolism estrogen 115–116, 117, 128 Gata4 158 culture environment role 171, 172 gay/lesbian reproduction 96, 97 differentiation of pluripotent ethics 93, 97–98, 99–100 cells 168 adult stem cells/iPS cells GCNA1 (germ-cell nuclear antigen 1) embryonic stem cells 165 93–94 5 hypoxia-inducible factors 173 efficiency of pregnancy GDNF 46–47 iPSCs 165, 169 establishment 99 pluripotency maintenance 164–165 embryo destruction 98 gene expression ESCs 94–97 embryonic stage-specific patterns gonadal niche 22, 26 ESCs derived from blastomeres 9, 80, 81 gonocytes 17, 52 93, 98 oocyte-to-embryo transition 77–78 PGCs 1, 2 graft rejection 111 gamete donation 93 fetal surgery 135–136 experimental autoimmune gene regulators, neural development immune system 99 158 encephalomyelitis (EAE) 146 graft vs.
Load more

Recommended publications
  • Resume of Kejin Hu
    CURRIULUM VITAE Of Kejin Hu PERSONAL INFORMATION Name: Kejin HU Visa status: USA citizen Language(s): English, Chinese Home city: Vestavia Hills, AL, 35226 RANK/TITLE, Assistant Professor Department: Biochemistry and Molecular Genetics Division: UAB Stem Cell Institute Business Address: SHEL 705, 1825 University Boulevard, Birmingham, AL, 35294 Phone: 205-934-4700 (office); 205-876-8693 (home); 205-703-6688 (cell) Fax: 205-975-3335 MEMBERSHIP: ISSCR (international Society for Stem Cell Research), since 2011 Member of Genetics Society of America (GSA, since 2006) EDUCATIONS June, 1999 to May, 2003, PhD, in marine molecular biology at the Department of Zoology, The University of Hong Kong, Hong Kong, China. July, 1995-October, 1997, MPhil, in fungal biochemistry/microbiology in the Hong Kong Polytechnic University. September, 1981-July, 1985, BSc in botany/agronomy at The Central China (Huazhong) Agricultural University, Wuhan, China. TEACHING EXPERIENCE: Advanced Stem Cell/Regenerative medicine, GBSC 709, Since 2014 SCIENTIFIC ACTIVITIES Ad hoc reviewer for the following journals: 1) Stem Cells; 2) Stem Cells and Development; 3) Stem Cell International; 4) Human Immunology; 5) Molecular Biotechnology; 6) Comparative Biochemistry and Physiology; 7) Journal of Heredity; 8) Scientific Reports; 9) Cellular Reprogramming; 10) Cell and Tissue Research; 11) Science Bulletin; 12) Reproduction, Fertility and Development. 1 Grant Reviewer for 1) Medical Research Council (MRC) of the United Kingdom (remote review, 2015); 2) New York Stem Cell Science (panel meeting from 09/28-09/30, 2016); 3) UAB internal grants SCIENTIFIC/ACADEMIC EXPERIENCE 2011 to present, Assistant Professor, Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL September, 2007 to July, 2011, Research Associate in human iPSC reprogramming and human pluripotent stem cell biology, and their differentiation into blood lineage, Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI.
    [Show full text]
  • 2012 Annual Report Stanford Institute for Stem Cell Biology and Regenerative Medicine
    2012 ANNUAL REPORT STANFORD INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE DOLOR SET AMET 1 MESSAGE FROM THE DIRECTOR The year 2012 was a pivotal one. We now have several discoveries coming from the Institute that are either at, or will soon be at, the clinical trial stage. With this in mind, we need to beef up our ability to carry out stem cell therapies at Stanford. The key to any stem cell therapy is to identify and isolate pure populations of stem cells in a sterile facility so that those cells can be administered to patients. I’m pleased to say that we now nearly have pledges of support to establish a Stem Cell Therapy Center at Stanford, which will allow us to isolate pure populations of stem cells and will make such clinical trials possible. This is a major partnership of Stanford Medicine: the Institute is partnering with Stanford Hospital, thanks to Amir Rubin, and with Lucille Packard Children’s Hospital, thanks to Chris Dawes. Our first cohort of patients at the new Stem Cell Therapy Center will be women with widespread, metastatic breast cancer. We will obtain their ‘mobilized blood,’ which contains blood-forming stem cells and also circulating cancer cells, and from that we will purify the stem cells of all cancer cells to safely regenerate their blood and immune cells after very high-dose chemotherapy. Years ago, a small clinical trial at Stanford using high-dose chemotherapy and these sorts of purified stem cell transplants led to 33% survival over the last 14 years among women with stage-four 1 breast cancer (while of those that received purified mobilized primary eating cells of the immune system, macrophages.
    [Show full text]
  • Director, the Turek Clinics Former Professor In
    June 15, 2020 CURRICULUM VITAE NAME: Paul Jacob Turek, M.D. PRESENT TITLE: Director, The Turek Clinics Former Professor in Residence Academy of Medical Educators Endowed Chair Department of Urology, Obstetrics, Gynecology and Reproductive Sciences University of California San Francisco TELEPHONE: Office: (415) 392-3200 DATE OF BIRTH July 8, 1960 CITIZENSHIP: United States of America EDUCATION: Manchester High School Connecticut High School Diploma, Salutatorian 1978 Yale College New Haven, Connecticut Degree: Bachelor of Science (Biology) 1982 Summa cum laude Stanford University School of Medicine Stanford, California Degree: M.D. (Research Honors) 1987 POST-GRADUATE TRAINING: Surgical Intern Hospital of the University of Pennsylvania 1987 - 1988 Philadelphia, Pennsylvania Surgical Resident Hospital of the University of Pennsylvania 1988 - 1989 Philadelphia, Pennsylvania Urology Resident Hospital of the University of Pennsylvania 1989 - 1993 and Instructor Philadelphia, Pennsylvania Fellow and Department of Urology 1993 - 1994 Instructor Baylor College of Medicine P.J.Turek, M.D.-2 6/15/20 Houston, Texas ACADEMIC APPOINTMENTS Assistant Clinical Department of Urology 1994 - 1995 Professor University of California San Francisco Assistant Professor Department of Urology 1995 - 2000 In Residence University of California San Francisco Clinical Assistant Department of Urology 1996 - 1998 Professor Stanford University Associate Professor Department of Urology 2000 - 2006 In Residence Department of Ob-Gyn and Reproductive Sciences University of California, San Francisco Endowed Chair Academy of Medical Educators 2006 - 2008 Professor in Residence Department of Urology 2006 - 2008 Department of Ob-Gyn and Reproductive Sciences University of California, San Francisco Faculty lecturer Yo San University of Traditional Chinese Medicine 2017- Santa Monica, CA HOSPITAL STAFF APPOINTMENTS: Moffitt Hospital-University of California 1994-2010 UCSF/Mt.
    [Show full text]
  • Dr. Mike Snyder Will Join Stanford As Chair of Genetics
    Dean’s Newsletter March 30, 2009 Table of Contents • Dr. Mike Snyder Will Join Stanford as Chair of Genetics • 2009 National Advisory Council Annual Review • AAMC Faculty Forward Program Begins • Further Updates on School of Medicine Financial Planning • Responding to the Stimulus • Public Transparency in Industry Relations • The 2009 Match • Upcoming Event: East-West Alliance Conference on Longevity • Stanford Postdoctoral Graduate Award • Application to the Arts Program • Awards and Honors • Appointments and Promotions Dr. Mike Snyder Will Join Stanford as Chair of Genetics I am extremely pleased to announce that Dr. Mike Snyder, Professor of Biology and Director of the Yale Center for Genomics and Proteomics, has accepted our offer to join Stanford as Chair of the Department of Genetics. Dr. Snyder was selected through a national search led by Dr. Lucy Shapiro, Ludwig Professor of Developmental Biology and Director of the Beckman Center. Dr. Snyder received his PhD from the California Institute of Technology and did a postdoctoral fellowship at Stanford with Dr. Ron Davis in the Department of Biochemistry. He joined the Yale faculty in 1986 where he also served as Chair of the Department of Molecular, Cellular and Developmental Biology (1998-2004). He has had a highly distinguished career and is the recipient of numerous awards and honors. He is the author of over 240 publications and is highly recognized for his leadership in genomics and genetics. In addition to serving as Chair of the Department of Genetics, Dr. Snyder will lead a new Center of Genomics and Personalized Medicine, which will provide a broad umbrella for school and university efforts in genomics and their application to diagnosing and managing human disease.
    [Show full text]
  • Renee a Reijo Pera, Phd Stanford University EDUCATION
    Renee A Reijo Pera, PhD Stanford University EDUCATION INSTITUTION AND LOCATION DEGREE YEAR SCIENTIFIC DISCIPLINE and MENTOR University of Wisconsin at B.S. 1983 Biology (Daryl Kaufmann) Superior (UWS) M.S. 1987 Entomology (Ted Hopkins) Kansas State University Cornell University Ph.D. 1993 Molecular Cell Biology (Tim Huffaker) Massachusetts Institute of Postdoc 1993-97 Human Genetics (David Page) Technology (MIT) PROFESSIONAL POSITIONS, HONORS AND AWARDS Professional Positions 2012- George D Smith Professor of Stem Cell Biology & Regenerative Medicine; Institute for Stem Cell Biology and Regenerative Medicine, Departments of Genetics and Obstetrics and Gynecology; Director, Center for Reproductive and Stem Cell Biology; Director, Center for Human Pluripotent Stem Cell Research and Education; Stanford University 2013- CoDirector Stanford:NIST ABMS (Advances in Biological Measurement Sciences program (other CoDirectors: Norbert Pelc (BioEngineering), Tom Baer (Applied Physics and Marc Salit (NIST)) 2013- Consultant, US Food and Drug Administration (FDA); Cellular, Tissue and Gene Therapies 2013- Founder; NovoVia, Inc; Palo Alto, CA (private-donor backed initiative intended to translate findings in the laboratory to use of stem cells to restore fertility in boys with cancer and other species (including endangered) 2012- Founder, Board of Directors; Cellogy, Inc, Menlo Park, CA (private-donor backed initiative intended to translate findings in the laboratory to imaging algorithms to predict neurodegeneration 2011- Founder, Scientific Advisor,
    [Show full text]
  • SPRC 2013 Agenda SPRC 2013 Annual Symposium September 16-18, 2013 Li Ka Shing Conference Center, Stanford University
    SPRC 2013 Annual Symposium September 16-18, 2013 Li Ka Shing Conference Center, Stanford University MONDAY, SEPTEMBER 16 8:00 – 8:15 Welcome Remarks Anton Muscatelli, Univ of Glasgow 8:15 – 9:00 Plenary: Black Silicon: From Serendipitous Discovery to Devices Eric Mazur, Harvard University Session 1: Ultrafast Materials Science Faculty Coordinator: Aaron Lindenberg 9 :00 – 9 :30 Turntable Ultrafast Responses in Graphene Feng Wang, UC Berkeley 9:30 – 10:00 Separating Electronic and Structural Phase Transitions in Alex Gray, Stanford University VO2 with THz-Pump X-Ray Probe Spectroscopy Coffee Break 10:00 – 10:30 Session 2: Laser Particle Accelerators Faculty Coordinator: Bob Byer 10:30 – 11:00 Recent Advances in Laser Acceleration of Particles Chan Joshi, UCLA 11:00 – 11:15 Electron Acceleration in a Laser-Driven Dielectric Micro- Edgar Peralta, Stanford Structure 11:15 – 11:45 All Laser-Driven Compton X-ray Light Source Donald Umstadter, Univ of Nebraska 11:45 – 12:00 Beam Control in Microaccelerators Ken Soong, Stanford 12:00 – 12:30 Poster Introductions Lunch & Poster Session 12:30 – 2:00 Session 3: X-Ray Imaging Faculty Coordinator: Bert Hesselink 2:00 – 2:30 Recent Results in Differential Phase Contrast Imaging Rebecca Fahrig, Stanford 2:30 – 2:45 Differential Phase Contrast Imaging for Aviation Security Max Yuen, Stanford Applications 2:45 – 3:15 Structured Illumination and Compressive X-ray David Brady, Duke University Tomography 3:15 – 3:30 Photo Electron X-ray Source Array Yao-Te Cheng, Stanford Coffee Break 3:30 – 4:00 Session
    [Show full text]
  • Accelerating Innovation in 21St Century Biosciences: Identifying the Measurement Standards and Technological Challenges
    Conference on Accelerating Innovation in 21st Century Biosciences: Identifying the Measurement Standards and Technological Challenges October 19-22, 2008 Gaithersburg, MD 2 Table of Contents Table of Contents Conference Welcome Letters...................................5-8 Sponsors................................................................9-14 Overview ................................................................... 15 Agenda.................................................................17-22 Biographies ..........................................................23-55 Exhibitors .................................................................. 55 General ..................................................................... 57 Transportation......................................................58-60 Organizing Committee .............................................. 61 Contact Information................................................... 62 Maps ....................................................................63-66 3 4 Welcome 19 October 2008 Dear Participants, On behalf of NIST and UMBI, it is our pleasure to welcome you to the international conference “Accelerating Innovation in 21st Century Biosciences: Identifying the Measurement, Standards and Technological Challenges” in Gaithersburg, Maryland. We see this as being a landmark event for the biosciences. Never before has there been a meeting that focuses on the measurement and standards barriers to innovation in the biosciences that are impeding the world from fully
    [Show full text]
  • 2009 Annual Report Efflorescence Ef·Flo·Res·Cence (Noun) a State Or Time of Flowering
    Institute for Stem Cell Biology & Regenerative Medicine 2009 Annual Report Efflorescence ef·flo·res·cence (noun) A state or time of flowering Seven years ago, the Stanford Institute for Stem Cell Biology and Regenerative medicine was founded with a view toward understanding how stem cells func- tion and using that information to repair and renew organs and tissues. We are now beginning to see that vision begin to blossom. Through the farsighted generosity of Lorry Lokey, as well as support from the California Institute for Regenerative Medicine, the new Lorry I. Lokey Stem Cell Research Building is now racing toward completion. Very shortly, researchers will be taking advan- tage of the building’s advanced facilities. to the institute: Marius Wernig, MD; Ravindra Majeti, MD, PhD, and Maximilian Diehn,We were MD, also PhD. fortunate These andyoung, gratified distinguished to have added researchers three new continue faculty an members impres- sive, ongoing expansion of the stem cell research program. In the last year, institute faculty have been spearheading the creation of a doc- toral program in stem cell biology. If ultimately approved by the university, this - cally different than developmental biology. Students from around the world havePhD program already exressed will be a interestsignificant in suchrecognition a program. that stem cell biology is categori As the Stanford stem cell research effort grows and blossoms, we look forward to the fruits of our labors—clinical trials of therapies that are based on the knowledge we have cultivated in institute laboratories. The year 2009 has been a landmark in that regard: the California Insitute for Regenerative Medicine (CIRM) has awarded major disease team research grants to Stanford stem cell researchers who intend to guide research out of the laboratory and into clinical trials within the next few years.
    [Show full text]
  • HHMI BULLETIN | May 2Oo8 President’S Letter
    HHMI BULLETIN M AY ’08 VOL.21 • NO.02 • 6]eO`R6c HHMI BULLETIN U VSa;SRWQOZ7\abWbcbS • eeeVV[W]` U Juan Young / Zoghbi lab Young Juan 23431BA7</A7<5:353<31/CA3@3BBAG<2@=;3/@/@3<3C@= Communication :=571/:µ/CB7A;A>31B@C;¶27A=@23@B6/B23AB@=GA;=B=@ 1==@27</B7=</<21=;;C<71/B7=<A97::A=457@:AE7B67<B63 47@ABG3/@=@A==4:7437<'''6C2/H=5607723<B74732B63 Breakdown 1C:>@7B;CB/B7=<A7<B6353<31/::32;31> /<20GABC2G7<5 B6327A=@23@7<;7136/A:3/@<32B6/BB63;31> >@=B37< 5@33<7A3F>@3AA327<3D3@G;/BC@3<3C@=<7<B630@/7< /<2@35C:/B3AB63/1B7D7BG=4=B63@53<3A7B¸A<=E=<23@ A63A/GAB6/B/23431B7<B6353<3E@3/9AAC166/D=1 <=EH=5607¸A5@=C>6/A27A1=D3@32/@=:34=@;31> /B B63AG</>B711=<<31B7=<03BE33<<3C@=<A´/</@3/=B63@ /CB7A;@3A3/@163@A/@34=1CA7<5=</AE3::A33>/53 "8]\Sa0`WRUS@]OR d]Z 1VSdg1VOaS;O`gZO\R &#$%&' eeeVV[W]`U \ ] ;/97<5;/B61=C<B@SOZe]`ZR[ObV^`]PZS[a[Og[OYSabcRS\baPSbbS`PW]Z]UWaba 7<B67A7AAC3/cbWa[¸a7\dWaWPZS0O``WS`aF7\OQbWdObW]\4WRUSbW\U3\hg[Sa =0A3@D/B7=<A 3;3@57<5AB@/<53@A EVS\^agQVWOb`Wab:S]9O\\S`]PaS`dSRQVWZR`S\W\bVS'!aO\R ^cbbW\UbVS¿Uc`SaW\b]bVSW`^`]^S`a^OQSaO\RbOYW\UbVS[]cbOUOW\ '"aeV]aVO`SRQS`bOW\c\[WabOYOPZSQVO`OQbS`WabWQaVSQ]W\SR OR`]WbZgO\R_cWQYZgEVS\W\bS`TS`SReWbVVSeVW\SRW[^ObWS\bZg bVSbS`[µW\TO\bWZSOcbWa[¶4`][bVSW`SO`ZWSabROgabVSQVWZR`S\¸a 6SRWR\]b`Sa^]\Rb]PSW\UQOZZSR]`b]O\g]bVS`e]`RaORR`SaaSR PSVOdW]`VSaOgaeOaµU]dS`\SR`WUWRZgO\RQ]\aWabS\bZgPgbVS b]VW[6SeOaQ][^ZSbSZgOPa]`PSRW\eVObSdS`VSRWR6S\SdS` ^]eS`TcZRSaW`ST]`OZ]\S\SaaO\RaO[S\Saa¶ a[WZSR6Sa][SbW[SacbbS`SRW\O`bWQcZObSa]c\RaW\O[]\]b]\]ca aW\Ua]\U[O\\S`/b]\SbW[SVSUS\bZgab`]YSRVWa[]bVS`¸aZSUO\R /QQ]`RW\Ub]VWa[]bVS`I6S`PS`bKeOaµOZeOgaaZ]eO\R_cWSb¶4]`
    [Show full text]
  • CHEM-BIOCHEM-2017-MSU.Pdf
    MONTANA STATE UNIVERSITY DEPARTMENT OF CHEMISTRY AND BIOCHEMISTRY FACULTY RESEARCH The graduate recruiting and admission committee, as well as the entire research active faculty of the Department of Chemistry and Biochemistry at Montana State University, would like to thank for your interest in this booklet. We are continuously looking for motivated graduate students with strong academic backgrounds in chemistry, biochemistry, or materials science, who are looking for cutting-edge research opportunities while pursuing a Ph.D. degree in our department. Please join us as the leading department at Montana State University in scientific discovery, research innovations, and research funding. Our department is proud to emphasize innovative, externally funded research programs that engage students in small research group settings with personal mentoring and individualized graduate programs of study. Students customize their coursework and quickly begin their independent scholarly research projects under the guidance of a research active faculty member. Many faculty are involved in collaborative research projects which offer students the unique opportunity to become simultaneously trained in chemical synthesis, characterization, instrumentation, theory, and modeling. We currently have a graduate student body of ~70 students, with an average time to degree of less than 6 years. All graduate students are appointed on either research or teaching assistantships and both appointments offer a tuition waiver and a competitive monthly stipend. Our community in Bozeman, Montana, is culturally rich and offers numerous recreational opportunities, while providing historically what only “The West” can offer. Undoubtedly, Bozeman’s location presents unparalleled natural beauty. We encourage all our students to take advantage of all the best that Montana can offer, while staying engaged in our laboratories and remaining competitive nationally and internationally.
    [Show full text]
  • 5Th International Meeting Stem Cell Network North Rhine-Westphalia
    5th International Meeting Stem Cell Network North Rhine-Westphalia _March 24th –25th, 2009 _Final Program _Poster Abstracts _Company Profiles _Contact _Program Tuesday, March 24th 8:00 - 9:00 am _ Registration SPP 1356 ‘Pluripotency & Reprogramming’: Reprogramming I, Chair: A. Müller 9:00 - 9:30 am _ Austin Cooney, Houston Alternative pathways to maintain pluripotency 9:30 - 10:00 am _ Theodore Rasmussen, Storrs, Connecticut Direct reprogramming of somatic cells: From ES cell fusion to iPS 10:00 - 10:30 am _ Paul Robson, Singapore Insights into blastocyst formation revealed by single cell analysis 10:30 - 11:00 am _ Miodrag Stojkovic, Valencia Potential of embryonic and adult stem cells 11:00 - 11:15 am _ Coffee Break, Poster Session 11:15 - 11:45 am Opening of the NRW-Meeting _Thomas Rachel (Parliamentary State Secretary of Education and Research) Keynote Lectures, Chair: H. Schöler 11:45 - 12:30 am _ John Gurdon, Cambridge, UK Nuclear reprogramming by eggs and oocytes 12:30 - 1:15 am _ Bartha Knoppers, Montreal Title to be announced 1:15 - 2:30 pm _ Lunch Break, Poster Session Reprogramming II, Chair: M. Zenke 2:30 - 3:00 pm _ Huck-Hui Ng, Singapore Deciphering and reconstruction of embryonic stem cell transcriptional regulatory network 3:00 - 3:30 pm _ Alexander Meissner, Cambridge, USA Dissecting the mechanism of reprogramming 3:30 - 4:00 pm _ Coffee Break, Poster Session Mechanisms Regulating the Stem Cell State, Chair: A. Faissner 4:00 - 4:30 pm _ Ian Chambers, Edinburgh Transcription factor control of ES cell self-renewal 4:30 - 4:45 pm _ Jens Schwamborn, Münster 4:45 - 5:15 pm _ Niall Dillon, London Combinatorial histone modifications and the epigenetic regulation of stem cell commitment and differentiation 5:15 - 6:45 pm Poster Session 7:00 - 10:30 pm _ Networking Event at the historic Aula Carolina (bus transport provided) Wednesday, March 25th 9:00 - 10:00 am _ Ethical Issues regarding Therapeutic Experiments (Panel Discussion) Stem Cell Differentiation, Chair: S.
    [Show full text]
  • CIRM California Institute for Regenerative Medicine Annual Report 2010 Autoimmune Diseases Arthritis Crohn’S
    CIRM California institute for regenerative MediCine annual report 2010 Autoimmune Diseases Arthritis Crohn’s Disease Devic’s Syndrome Multiple Sclerosis Osteoporosis Systemic Lupus Erythematosus (Lupus) Systemic Sclerosis Type 1 Diabetes Cancers Bladder Brain/Central Nervous System Breast Colon/Lower Bowel Endometrium/Cervix Ovary Esophagus Kidney Leukemia Liver Lungs/Respiratory System Lymphoma Myeloma Oral Cavity Pancreas Prostate Skin Stomach Cardiovascular Diseases Acute Ischemic Heart Disease (angina) Myocardial Infarction (heart attack) Chronic Ischemic Heart Disease (athersclerotic heart disease) Cardiomyopathy Cerebrovascular Disease (stroke) Circulatory/Respiratory Diseases Chronic Obstructive Pulmonary Disease Pulmonary Fibrosis Injuries Severe Burns Spinal Cord Injury Eye Disorders t u rnin g s t em ce l l s in t o C u re s Macular Degeneration Retinitis Pigmentosa Infectious Diseases HIV/AIDS Metabolic Diseases Adrenoleukodystrophy Aspartylglycosaminuria Canavan’s Disease Cystic Fibrosis Fabry Disease Fucosidosis Gaucher Disease Leukodystrophy “During this time of uncertainty at the federal level, with a continuing potential for NIH shutdown by lawsuit, California carries on as a leader in funding Mucopolysaccharidoses Niemann-Pick Disease Pompe Disease Porphyria stem cell research, as approved by California voters. To date, over $1 billion Sickle Cell Disease Tay-Sachs Disease Type 2 Diabetes Muscular Dystrophies in bonds have been sold to invest here on the frontier of medical science, in research that promises hope for more
    [Show full text]